Association of recanalization of the left umbilical vein with umbilical hernia in patients with liver disease
Eran Shlomovitz, Douglas Quan, Roya Etemad‐Rezai, Vivian C. McAlister – 23 September 2005
Living domino liver transplantation in an adult with congenital absence of portal vein
Takayuki Takeichi, Hideaki Okajima, Hiroko Suda, Shintarou Hayashida, Hironori Iwasaki, Manuel Zeledon Ramirez, Mikako Ueno, Katsuhiro Asonuma, Yukihiro Inomata – 23 September 2005 – Congenital absence of the portal vein (CAPV) is a rare malformation of the splanchnic venous system. Although CAPV is usually detected in the pediatric age group, our patient was a 35‐year‐old woman. She had been diagnosed with CAPV in 1996 when she was 27 years old. In 1998, she was placed on hemodialysis due to chronic renal failure.
Resection for hepatocellular carcinoma is a good option in Child‐Turcotte‐Pugh class A patients with cirrhosis who are eligible for liver transplantation
Carlos Margarit, Alfredo Escartín, Lluis Castells, Víctor Vargas, Elena Allende, Itxarone Bilbao – 23 September 2005 – The best treatment option for patients with single, early hepatocellular carcinoma (HCC) and cirrhosis, good liver function, and absence of portal hypertension remains to be established. The aim of this work was to compare the outcome of liver resection (LR) with that of liver transplantation (LT) for single, early HCC in Child‐Turcotte‐Pugh class A patients with cirrhosis younger than 70 years of age.
Highlights in Liver Transplantation
23 September 2005
Gc‐globulin to predict outcome in acute liver failure: A panacea?
Rajiv Jalan – 23 September 2005
Early HCV‐associated stellate cell activation in aggressive recurrent HCV: What can liver allografts teach about HCV pathogenesis?
Anthony J. Demetris, John G. Lunz – 23 September 2005
Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation
Samer Gawrieh, Bettina G. Papouchado, Lawrence J. Burgart, Shogo Kobayashi, Michael R. Charlton, Gregory J. Gores – 23 September 2005 – Only a subset of hepatitis C virus (HCV)‐infected patients develop progressive hepatic fibrosis after liver transplantation (LT). Hepatic stellate cell (HSC) activation is a pivotal step in hepatic fibrosis and precedes clinically apparent fibrosis. We determined whether early HSC activation, measured in 4‐month protocol post‐LT biopsies, is predictive of subsequent development of more histologically severe recurrence of HCV.
Recurrent herpes simplex virus hepatitis after liver retransplantation despite acyclovir therapy
Thomas Longerich, Christoph Eisenbach, Roland Penzel, Thomas Kremer, Christa Flechtenmacher, Burkhard Helmke, Jens Encke, Thomas Kraus, Peter Schirmacher – 23 September 2005 – Herpes virus hepatitis (HSV) represents a form of acute necrotizing hepatitis, which most frequently develops in immunocompromised patients. Therapeutic options include high‐dose intravenous acyclovir and liver transplantation. We report the first case of recurrent HSV hepatitis after liver retransplantation, which occurred despite continuous administration of high‐dose intravenous antiviral therapy.
Nodular regenerative hyperplasia and thiopurines: The case for level‐dependent toxicity
Nanne K. H. de Boer, Chris J.J. Mulder, Adriaan A. van Bodegraven – 23 September 2005
Sequence of reperfusion influences ischemia/reperfusion injury and primary graft function following porcine liver transplantation
Jens G. Brockmann, Christian August, Heiner H. Wolters, Ralf Hömme, Daniel Palmes, Hideo Baba, Hans‐U. Spiegel, Karl H. Dietl – 23 September 2005 – The impact of 3 different reperfusion sequences following orthotopic liver transplantation (OLT) in pigs were evaluated. The reperfusion technique commonly performed is primary portal in order to shorten warm ischemic times (WITs). Experimental and clinical data, usually comparing 2 out of 3 possible reperfusion sequences, provide controversial results.